Petros Pharmaceuticals, Inc. (PTPI) Cash Flow Statement
Where PTPI’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$6.7M
- Capital expenditures
- $0
- Free cash flow
- −$6.7M
- Returned to shareholders
- $974.3M
- Change in cash
- $1.4M cash at year-end $5.1M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PTPI operating cash flow, capex and free cash flow
PTPI cash flow trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $8.0M2018 | −$6.7M2025 | — | |
| Capital expenditures | $1.9M2018 | $02025 | −100.0% | |
| Free cash flow | $6.1M2018 | −$6.7M2025 | — | |
| Free cash flow margin | 43.7%2018 | −51.4%2024 | −95.1 pts | |
| Stock-based compensation | $5.4M2019 | $304,6342025 | −38.1%/yr | |
| Dividends paid | $556.7M2023 | $974.0M2025 | +32.3%/yr | |
| Share buybacks (net) | $02022 | $341,5602025 | — | |
| Capex / revenue | 13.3%2018 | 0.5%2024 | −12.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PTPI cash flow by activity
PTPI net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PTPI cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net income | $2.5M | −$14.3M | −$8.2M | −$20.0M | −$9.0M | −$20.6M | −$32.5M | −$32.5M |
| Depreciation & amortization | — | $2.9M | $3.4M | $5.7M | $6.9M | $6.7M | $5.3M | $8.1M |
| Stock-based compensation | $304,634 | $197,215 | $417,230 | $1.2M | $1.3M | $3.6M | $5.4M | — |
| Change in working capital | −$663,598 | $4.5M | $624,914 | −$3.3M | −$1.8M | −$5.6M | $13.1M | $4.9M |
| Other non-cash items | −$8.8M | $4.0M | −$3.9M | $3.6M | −$9.3M | $586,145 | $11.3M | $27.5M |
| Cash from operating activities | −$6.7M | −$2.6M | −$7.6M | −$12.8M | −$11.9M | −$15.3M | $2.5M | $8.0M |
| Investing activities | ||||||||
| Capital expenditures | $0 | −$24,587 | −$1 | $0 | $0 | −$4,633 | −$71,540 | −$1.9M |
| Investments (net) | — | −$24,587 | $0 | — | $0 | −$4,633 | −$71,540 | — |
| Acquisitions & other investing | — | $24,587 | — | — | — | $4,633 | $71,540 | $0 |
| Cash from investing activities | — | −$24,587 | — | — | — | −$4,633 | −$71,540 | −$1.9M |
| Financing activities | ||||||||
| Dividends paid | −$974.0M | −$1.29B | −$556.7M | — | — | — | — | — |
| Share repurchases & issuance (net) | −$341,560 | −$6.2M | −$2.0M | $0 | — | — | — | — |
| Net borrowing (repayment) | $0 | −$765,279 | −$1.5M | −$1.6M | −$7.2M | $8.8M | −$3.1M | −$2.5M |
| Shares issued | $8.5M | $0 | $15.0M | $0 | $21.7M | $0 | $0 | $0 |
| Other financing | $974.0M | $1.29B | $556.7M | $0 | $4.0M | $21.5M | $0 | $0 |
| Cash from financing activities | $8.2M | −$7.0M | $11.5M | −$1.6M | $18.6M | $30.3M | −$3.1M | −$2.5M |
| Summary | ||||||||
| Net change in cash | $1.4M | −$9.6M | $3.9M | −$14.4M | $6.7M | $15.0M | −$648,313 | $3.6M |
| Cash at end of period | $5.1M | $3.7M | $13.3M | $9.4M | $23.8M | $17.1M | $2.1M | $2.8M |
| Free cash flow | −$6.7M | −$2.6M | −$7.6M | −$12.8M | −$11.9M | −$15.3M | $2.5M | $6.1M |
| Free cash flow margin | — | −51.4% | −131.0% | −213.6% | −151.9% | −160.2% | 15.8% | 43.7% |
| Capex / revenue | — | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 13.3% |
| Operating cash flow / net income | −2.72 | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$955,625 | −$987,036 | −$336,506 | −$922,723 | $4.9M | −$1.2M | −$9.3M | −$2.2M | $384,287 | $382,893 | −$5.0M | −$4.5M |
| Depreciation & amortization | — | — | — | $707,805 | — | — | $667,294 | $768,260 | $754,667 | $753,527 | $934,794 | $860,336 |
| Stock-based compensation | $117,906 | $120,319 | $75,138 | $75,137 | $74,321 | $80,038 | −$270,000 | $60,000 | $16,834 | $180,381 | $212,738 | $30,840 |
| Change in working capital | −$82,445 | $82,445 | −$670,476 | −$285,338 | $456,288 | −$164,072 | $2.2M | −$55,942 | −$48,166 | $16,607 | $1.6M | −$1.8M |
| Other non-cash items | $56,309 | $0 | −$1,700 | −$708,805 | −$8.5M | −$376,513 | $7.6M | $677,097 | −$2.8M | −$2.5M | −$37,775 | $1.4M |
| Cash from operating activities | −$863,855 | −$784,272 | −$933,544 | −$1.1M | −$3.0M | −$1.7M | $965,405 | −$771,246 | −$1.7M | −$1.1M | −$2.3M | −$4.0M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | −$5,449 | −$19,138 | −$2 | $0 | $0 | $0 |
| Investments (net) | — | — | — | — | — | — | −$5,449 | — | — | — | — | — |
| Acquisitions & other investing | — | — | — | — | — | — | $5,449 | $0 | — | — | — | — |
| Cash from investing activities | — | — | — | — | — | — | −$5,449 | −$19,138 | — | — | — | — |
| Financing activities | ||||||||||||
| Dividends paid | −$465,524 | −$232,822 | — | −$449,400 | — | −$275,167 | −$691.8M | −$390.7M | — | −$556.7M | — | — |
| Share repurchases & issuance (net) | — | — | $0 | −$117,311 | −$224,249 | $0 | −$1.1M | $2.7M | −$1.6M | −$1.1M | — | $0 |
| Net borrowing (repayment) | — | — | — | — | — | — | $0 | −$385,488 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $8.7M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $465,524 | $8.15B | $0 | $449,400 | −$203,984 | $275,167 | $691.8M | $385.6M | −$379,791 | $556.7M | −$2.4M | $14.6M |
| Cash from financing activities | $0 | $8.15B | $0 | −$117,311 | −$428,233 | $8.7M | −$1.1M | −$2.8M | −$2.0M | −$1.1M | −$2.4M | $14.6M |
| Summary | ||||||||||||
| Net change in cash | −$863,855 | −$784,272 | −$933,544 | −$1.3M | −$3.4M | $7.0M | −$184,714 | −$3.6M | −$3.6M | −$2.3M | −$4.6M | $10.6M |
| Cash at end of period | $3.5M | $4.4M | $5.1M | $6.1M | $7.3M | $10.8M | $3.7M | $3.9M | $7.5M | $11.1M | $13.3M | $18.0M |
| Free cash flow | −$863,855 | −$784,272 | −$933,544 | −$1.1M | −$3.0M | −$1.7M | $959,956 | −$790,384 | −$1.7M | −$1.1M | −$2.3M | −$4.0M |
| Free cash flow margin | — | — | — | — | — | — | 132.3% | −50.1% | −116.9% | −81.7% | — | −241.6% |
| Capex / revenue | — | — | — | — | — | — | 0.8% | 1.2% | 0.0% | 0.0% | — | 0.0% |
| Operating cash flow / net income | — | — | — | — | −0.61 | — | — | — | −4.33 | −2.96 | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PTPI cash generation
In fiscal 2025 (ended December 31, 2025), Petros Pharmaceuticals generated -$6.7 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$6.7 million. It returned $974.3 million to shareholders through dividends ($974.0 million) and net share buybacks ($0.3 million). Cash and equivalents rose by $1.4 million over the year.
Related: PTPI income statement, PTPI balance sheet. See the PTPI stock overview for the latest quote and news.
PTPI cash flow FAQ
What is Petros Pharmaceuticals's free cash flow?
Petros Pharmaceuticals's free cash flow was -$6.7 million in fiscal 2025: -$6.7 million of operating cash flow minus $0 of capital expenditures It was -$2.6 million a year earlier..
How much cash does Petros Pharmaceuticals generate from operations?
Petros Pharmaceuticals generated -$6.7 million of cash from operating activities in fiscal 2025, −2.72 times its net income of $2.5 million.
How much stock does Petros Pharmaceuticals buy back?
Petros Pharmaceuticals spent $0.3 million on net share repurchases in fiscal 2025.
How much does Petros Pharmaceuticals pay in dividends?
Petros Pharmaceuticals paid $974.0 million in dividends in fiscal 2025.